Repare Therapeutics Inc. (NASDAQ:RPTX) Receives Consensus Recommendation of "Hold" from Analysts

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) has been given an average recommendation of "Hold" by the seven brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $3.50.

RPTX has been the topic of several analyst reports. Wall Street Zen raised shares of Repare Therapeutics to a "hold" rating in a report on Saturday, November 15th. TD Cowen lowered Repare Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, November 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Repare Therapeutics in a report on Wednesday, October 8th. HC Wainwright reduced their target price on Repare Therapeutics from $5.00 to $3.00 and set a "buy" rating on the stock in a report on Monday, October 27th. Finally, Cowen cut Repare Therapeutics to a "hold" rating in a research note on Monday.

Get Our Latest Research Report on Repare Therapeutics

Institutional Investors Weigh In On Repare Therapeutics

Several hedge funds have recently bought and sold shares of the company. Quinn Opportunity Partners LLC acquired a new position in shares of Repare Therapeutics in the 2nd quarter valued at $56,000. Affinity Asset Advisors LLC boosted its position in shares of Repare Therapeutics by 100.0% during the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company's stock worth $197,000 after buying an additional 100,000 shares during the period. Acadian Asset Management LLC grew its stake in shares of Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company's stock worth $624,000 after acquiring an additional 168,230 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Repare Therapeutics in the 3rd quarter valued at $115,000. Finally, Rangeley Capital LLC bought a new stake in Repare Therapeutics during the second quarter worth about $494,000. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Stock Up 0.5%

Repare Therapeutics stock traded up $0.01 during trading hours on Friday, hitting $2.11. The stock had a trading volume of 1,178,199 shares, compared to its average volume of 1,054,180. The company has a 50-day moving average of $1.82 and a two-hundred day moving average of $1.61. Repare Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.07. The company has a market cap of $90.71 million, a PE ratio of -1.25 and a beta of 1.06.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last released its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.43. The firm had revenue of $11.62 million for the quarter, compared to the consensus estimate of $7.50 million. As a group, analysts forecast that Repare Therapeutics will post -2.04 EPS for the current fiscal year.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.

Featured Stories

• Five stocks we like better than Repare Therapeutics
• Bank Stocks - Best Bank Stocks to Invest In
• Attention Income Investors: This REIT Is on Sale
• ESG Stocks, What Investors Should Know
• Rocket Lab Just Had Its First Real Crash—The Rebound Could Be Bigger
• Dividend Capture Strategy: What You Need to Know
• MarketBeat Week in Review – 11/17 - 11/21

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Repare Therapeutics Right Now?

Before you consider Repare Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repare Therapeutics wasn't on the list.

While Repare Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here